Abstract

Converging clinical data suggest that peripheral inflammation is likely involved in the pathogenesis of the neuropsychiatric symptoms associated with metabolic syndrome (MetS). However, the question arises as to whether the increased prevalence of behavioral alterations in MetS is also associated with central inflammation, i.e. cytokine activation, in brain areas particularly involved in controlling behavior. To answer this question, we measured in a mouse model of MetS, namely the diabetic and obese db/db mice, and in their healthy db/+ littermates emotional behaviors and memory performances, as well as plasma levels and brain expression (hippocampus; hypothalamus) of inflammatory cytokines. Our results shows that db/db mice displayed increased anxiety-like behaviors in the open-field and the elevated plus-maze (i.e. reduced percent of time spent in anxiogenic areas of each device), but not depressive-like behaviors as assessed by immobility time in the forced swim and tail suspension tests. Moreover, db/db mice displayed impaired spatial recognition memory (hippocampus-dependent task), but unaltered object recognition memory (hippocampus-independent task). In agreement with the well-established role of the hippocampus in anxiety-like behavior and spatial memory, behavioral alterations of db/db mice were associated with increased inflammatory cytokines (interleukin-1β, tumor necrosis factor-α and interleukin-6) and reduced expression of brain-derived neurotrophic factor (BDNF) in the hippocampus but not the hypothalamus. These results strongly point to interactions between cytokines and central processes involving the hippocampus as important contributing factor to the behavioral alterations of db/db mice. These findings may prove valuable for introducing novel approaches to treat neuropsychiatric complications associated with MetS.

Highlights

  • For several decades, the prevalence of the metabolic syndrome (MetS) and related comorbidities continuously increases worldwide at alarming rate

  • We have found in mice that the selective activation of enzymatic pathways involved in brain monoamine metabolism by interferon-c (IFN-c) and tumor necrosis factor-a (TNF-a) mediates development of depressive-like behaviors in response to chronic infection [24,25,26]

  • Our study allows for the first time to directly relate in db/db mice increased anxiety-like behaviors and impaired spatial memory performances with activation of specific inflammatory pathways within the hippocampus, a key brain area for the control of emotional and cognitive behaviors

Read more

Summary

Introduction

The prevalence of the metabolic syndrome (MetS) and related comorbidities continuously increases worldwide at alarming rate. Mounting evidence suggests that systemic inflammation, higher peripheral IL-6, is associated with brain inflammation [35,36] that might adversely affect mood, learning and memory through processes related to neurodegeneration and structural remodeling [37,38,39]. Clinical studies in patients with MetS only assess systemic inflammation and it is still unknown if enhanced cytokine production associated with neuropsychiatric disorders in MetS does exist in brain areas involved in controlling behavior, the hippocampus. In this context, corollary questions arise as to whether all neuropsychiatric symptoms are affected in MetS and which inflammatory pathways are potentially activated in the hippocampus. According to the role of the hippocampus in emotional and cognitive behaviors [43,44] we hypothesized that the behavioral deficits of db/db mice would be associated with activation of cytokine pathways in the hippocampus

Results
Discussion
Findings
Materials and Methods
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call